Pre-extensively drug-resistant tuberculosis among multidrug-resistant tuberculosis patients in Ethiopia: a laboratory-based surveillance study.
drug-resistant tuberculosis
multidrug-resistant tuberculosis
pre-extensively drug-resistant
Journal
IJID regions
ISSN: 2772-7076
Titre abrégé: IJID Reg
Pays: England
ID NLM: 9918418183106676
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
received:
09
06
2022
revised:
25
08
2022
accepted:
25
08
2022
entrez:
30
9
2022
pubmed:
1
10
2022
medline:
1
10
2022
Statut:
epublish
Résumé
The rise of drug-resistant tuberculosis (DR-TB) has presented a substantial challenge to the national tuberculosis (TB) control program. Understanding the epidemiology of pre-extensively drug-resistant tuberculosis (pre-XDR-TB) could help clinicians to adapt MDR-TB treatment regimens at an earlier stage. This study aimed to assess second-line anti-TB drug resistance among MDR-TB patients in Ethiopia using routine laboratory-based data. Laboratory-based cross-sectional data were collected from the national TB reference laboratory and seven regional tuberculosis culture laboratories in Ethiopia from July 2019 to March 2022. The required data, such as drug-susceptibility testing (DST) results and sociodemographics, were collected on a structured checklist from laboratory registration books and electronic databases. Data were entered into a Microsoft Excel spreadsheet and analyzed using SPSS version 23. Descriptive statistics were performed to show the distribution and magnitude of drug resistance. Second-line drugs (SLDs) susceptibility testing was performed for 644 MDR isolates, of which 19 (3%) were found to be pre-XDR-TB cases. Of the total MDR-TB isolates, 19 (3%) were resistant to at least one fluoroquinolone drug, while 11 (1.7%) were resistant to at least one injectable second-line drug. Of the 644 MDR-TB isolates, 1.9% (5/261) pre-XDR were from new MDR-TB cases, while 3.7% (14/383) were from previously treated MDR-TB patients. The most frequently identified mutations, based on MTBDR The overall prevalence of pre-XDR-TB in Ethiopia is considerable. The majority of SLD resistance mutations were in the
Sections du résumé
Background
UNASSIGNED
The rise of drug-resistant tuberculosis (DR-TB) has presented a substantial challenge to the national tuberculosis (TB) control program. Understanding the epidemiology of pre-extensively drug-resistant tuberculosis (pre-XDR-TB) could help clinicians to adapt MDR-TB treatment regimens at an earlier stage. This study aimed to assess second-line anti-TB drug resistance among MDR-TB patients in Ethiopia using routine laboratory-based data.
Methods
UNASSIGNED
Laboratory-based cross-sectional data were collected from the national TB reference laboratory and seven regional tuberculosis culture laboratories in Ethiopia from July 2019 to March 2022. The required data, such as drug-susceptibility testing (DST) results and sociodemographics, were collected on a structured checklist from laboratory registration books and electronic databases. Data were entered into a Microsoft Excel spreadsheet and analyzed using SPSS version 23. Descriptive statistics were performed to show the distribution and magnitude of drug resistance.
Results
UNASSIGNED
Second-line drugs (SLDs) susceptibility testing was performed for 644 MDR isolates, of which 19 (3%) were found to be pre-XDR-TB cases. Of the total MDR-TB isolates, 19 (3%) were resistant to at least one fluoroquinolone drug, while 11 (1.7%) were resistant to at least one injectable second-line drug. Of the 644 MDR-TB isolates, 1.9% (5/261) pre-XDR were from new MDR-TB cases, while 3.7% (14/383) were from previously treated MDR-TB patients. The most frequently identified mutations, based on MTBDR
Conclusion
UNASSIGNED
The overall prevalence of pre-XDR-TB in Ethiopia is considerable. The majority of SLD resistance mutations were in the
Identifiants
pubmed: 36176268
doi: 10.1016/j.ijregi.2022.08.012
pii: S2772-7076(22)00105-9
pmc: PMC9513164
doi:
Types de publication
Journal Article
Langues
eng
Pagination
39-43Subventions
Organisme : FIC NIH HHS
ID : D43 TW009127
Pays : United States
Informations de copyright
© 2022 The Author(s).
Références
Int J Tuberc Lung Dis. 2008 Jan;12(1):99-104
pubmed: 18173885
PLoS One. 2020 Mar 4;15(3):e0229419
pubmed: 32130233
PLoS One. 2020 Feb 13;15(2):e0229040
pubmed: 32053661
Indian J Med Res. 2016 Mar;143(3):341-7
pubmed: 27241648
J Clin Microbiol. 2012 Jul;50(7):2404-13
pubmed: 22553245
J Clin Microbiol. 2016 Jun;54(6):1573-1580
pubmed: 27053671
Antimicrob Agents Chemother. 2018 Feb 23;62(3):
pubmed: 29311078
Infect Drug Resist. 2018 Oct 01;11:1627-1634
pubmed: 30319279
Antimicrob Resist Infect Control. 2021 Aug 26;10(1):126
pubmed: 34446095
Braz J Infect Dis. 2012 Mar-Apr;16(2):136-41
pubmed: 22552454
Infect Drug Resist. 2021 Mar 17;14:1089-1104
pubmed: 33762833
PLoS One. 2021 Jan 28;16(1):e0245687
pubmed: 33507946
Infect Drug Resist. 2019 Jan 10;12:211-219
pubmed: 30666136
Int J Tuberc Lung Dis. 2018 Jan 1;22(1):54-59
pubmed: 29297426